杜朝阳,程 丹,李 凤,孔令洋,盛 晟,程晓昱.益肾活血解毒汤治疗肾虚血瘀型颈动脉粥样硬化患者的疗效观察[J].现代生物医学进展英文版,2024,(5):985-989. |
益肾活血解毒汤治疗肾虚血瘀型颈动脉粥样硬化患者的疗效观察 |
Effect of Yishen Huoxue Jiedu Decoction on Carotid Atherosclerosis of Kidney Deficiency and Blood Stasis Type |
Received:July 06, 2023 Revised:July 28, 2023 |
DOI:10.13241/j.cnki.pmb.2024.05.034 |
中文关键词: 益肾活血解毒汤 颈动脉粥样硬化 肾虚血瘀型 疗效观察 炎性因子 |
英文关键词: Yishen Huoxue Jiedu Tang Carotid atherosclerosis Kidney deficiency and blood stasis type Observation of therapeutic effects Inflammatory factors |
基金项目:安徽省科技厅中药研究与开发-安徽省重点实验室开放基金项目(AKLPDCM202006) |
|
Hits: 220 |
Download times: 176 |
中文摘要: |
摘要 目的:观察益肾活血解毒汤治疗肾虚血瘀型颈动脉粥样硬化(CAS)效果。方法:选取我院2021年8月~2023年4月收治的肾虚血瘀型CAS患者80例,随机分为观察组和对照组,各40例。两组均予以常规西医治疗,观察组加服益肾活血解毒汤,治疗周期为四周。观察两组的临床疗效、血脂等指标变化,并进行统计学比较。结果:两组治疗前中医证候积分无差异(P>0.05),而治疗后,观察组中医证候积分明显低于对照组(P<0.05);观察组总有效率(97.50%)虽在数值上高于对照组(92.50%),但并无统计学意义(P>0.05);相较于治疗前,两组治疗后血脂指标(CHOL、TG、LDL-C)和炎性因子(NLRP3、Caspase-1、IL-1β、IL-18)水平显著下降(P<0.05),而观察组下降幅度更大,与对照组差异显著(P<0.05);服药期间,两组均无明显不良反应发生。结论:常规调脂抗动脉粥样硬化联合益肾活血解毒汤治疗肾虚血瘀型CAS疗效肯定,可有效改善临床症状,调节血脂水平,控制炎症反应,且安全性良好。 |
英文摘要: |
ABSTRACT Objective: To observe the effect of Yishen Huoxue Jiedu Decoction on carotid atherosclerosis (CAS) of kidney deficiency and blood stasis type. Methods: 80 patients with kidney deficiency and blood stasis type CAS admitted to our hospital from August 2021 to April 2023 were randomly divided into an observation group and a control group, with 40 patients in each group. Both groups were treated with conventional Western medicine, while the observation group was given Yishen Huoxue Jiedu Tang, with a treatment period of four weeks. Observe and compare the clinical efficacy, changes in blood lipids and other indicators between the two groups. Results: There was no significant difference in the TCM syndrome score between the two groups before treatment (P>0.05), but after treatment, the TCM syndrome score in the observation group was significantly lower than that in the control group (P<0.05). The total effective rate of the observation group (97.50%) was numerically higher than that of the control group (92.50%), but there was no statistical significance (P>0.05). Compared to before treatment, the levels of blood lipid indicators (CHOL, TG, LDL-C) and inflammatory factors(NLRP3, Caspase-1, IL-1β,IL-18) in the two groups significantly decreased after treatment (P<0.05), while the observed group showed a significant decrease compared to the control group (P<0.05). During the medication period, there were no significant adverse reactions in both groups. Conclusion: The conventional lipid regulating anti atherosclerosis combined with Yishen Huoxue Jiedu Decoction has a positive effect on the treatment of CAS of kidney deficiency and blood stasis type, which can effectively improve the clinical symptoms of patients, regulate the level of blood lipids, control inflammatory reactions, and has good safety. It is worth recommending. |
View Full Text
View/Add Comment Download reader |
Close |